{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:51:59Z","timestamp":1793332319490,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202212"],"award-info":[{"award-number":["82202212"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82100352"],"award-info":[{"award-number":["82100352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Anhui Medical University Research Fund","award":["2023xkj129"],"award-info":[{"award-number":["2023xkj129"]}]},{"name":"Tianjin Medical University General Hospital \u201cNew Century Talents\u201d Cultivation Project","award":["XSJ-2021\u201302"],"award-info":[{"award-number":["XSJ-2021\u201302"]}]},{"name":"Tianjin Medical University General Hospital Young and Middle-Aged Scientific Research Cultivation Fund","award":["303078100501"],"award-info":[{"award-number":["303078100501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07338-w","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:23:31Z","timestamp":1763735011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-0790","authenticated-orcid":false,"given":"Ningning","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinquan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongzhe","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"7338_CR1","doi-asserted-by":"crossref","unstructured":"Ali I, Alsehli M, Scotti L, Tullius Scotti M, Tsai ST, Yu RS, et al. Progress in polymeric nano-medicines for theranostic cancer treatment. Polym (Basel). 2020;12.","DOI":"10.3390\/polym12030598"},{"key":"7338_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","volume":"25","author":"NS Sherafat","year":"2025","unstructured":"Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Exp Med. 2025;25:238.","journal-title":"Clin Exp Med"},{"key":"7338_CR3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2174\/0929867323666160405111152","volume":"23","author":"I Ali","year":"2016","unstructured":"Ali I, Lone MN, Suhail M, Mukhtar SD, Asnin L. Advances in nanocarriers for anticancer drugs delivery. Curr Med Chem. 2016;23:2159\u201387.","journal-title":"Curr Med Chem"},{"key":"7338_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/157340613804488297","volume":"9","author":"I Ali","year":"2013","unstructured":"Ali I, Wani WA, Saleem K, Wesselinova D, Syntheses. DNA binding and anticancer profiles of L-glutamic acid ligand and its copper(II) and ruthenium(III) complexes. Med Chem. 2013;9:11\u201321.","journal-title":"Med Chem"},{"key":"7338_CR5","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95:20211033.","journal-title":"Br J Radiol"},{"key":"7338_CR6","doi-asserted-by":"publisher","first-page":"103187","DOI":"10.1016\/j.jaut.2024.103187","volume":"144","author":"S Fischer","year":"2024","unstructured":"Fischer S, Meisinger C, Freuer D. Autoimmune diseases and female-specific cancer risk: A systematic review and meta-analysis. J Autoimmun. 2024;144:103187.","journal-title":"J Autoimmun"},{"key":"7338_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/acr.24784","volume":"75","author":"A Wetzman","year":"2023","unstructured":"Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B, et al. Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with Meta-Analysis. Arthritis Care Res (Hoboken). 2023;75:260\u201371.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7338_CR8","first-page":"e8094","volume":"12","author":"F Angum","year":"2020","unstructured":"Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The prevalence of autoimmune disorders in women: A narrative review. Cureus. 2020;12:e8094.","journal-title":"Cureus"},{"key":"7338_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fendo.2019.00265","volume":"10","author":"MK Desai","year":"2019","unstructured":"Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Front Endocrinol (Lausanne). 2019;10:265.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7338_CR10","doi-asserted-by":"publisher","first-page":"188482","DOI":"10.1016\/j.bbcan.2020.188482","volume":"1875","author":"A Rajan","year":"2021","unstructured":"Rajan A, Nadhan R, Latha NR, Krishnan N, Warrier AV, Srinivas P. Deregulated Estrogen receptor signaling and DNA damage response in breast tumorigenesis. Biochim Biophys Acta Rev Cancer. 2021;1875:188482.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"7338_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10911-014-9324-x","volume":"19","author":"EF Need","year":"2014","unstructured":"Need EF, Atashgaran V, Ingman WV, Dasari P. Hormonal regulation of the immune microenvironment in the mammary gland. J Mammary Gland Biol Neoplasia. 2014;19:229\u201339.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"7338_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","volume":"36","author":"D Wang","year":"2015","unstructured":"Wang D, DuBois RN. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015;36:1085\u201393.","journal-title":"Carcinogenesis"},{"key":"7338_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759\u201371.","journal-title":"Nat Rev Cancer"},{"key":"7338_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cac2.12283","volume":"42","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Liu H, Yang Y, Zhou J, Zhao L, Chen H, et al. The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. Cancer Commun (Lond). 2022;42:435\u201346.","journal-title":"Cancer Commun (Lond)"},{"key":"7338_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0961203316664595","volume":"26","author":"S Bernatsky","year":"2017","unstructured":"Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, et al. Breast cancer in systemic lupus. Lupus. 2017;26:311\u20135.","journal-title":"Lupus"},{"key":"7338_CR16","doi-asserted-by":"publisher","first-page":"1029884","DOI":"10.3389\/fimmu.2022.1029884","volume":"13","author":"W Li","year":"2022","unstructured":"Li W, Wang R, Wang W. Exploring the causality and pathogenesis of systemic lupus erythematosus in breast cancer based on Mendelian randomization and transcriptome data analyses. Front Immunol. 2022;13:1029884.","journal-title":"Front Immunol"},{"key":"7338_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CEJ.0000000000000667","volume":"31","author":"C Gong","year":"2022","unstructured":"Gong C, Xu R, Zou P, Zhang Y, Wang X. Inflammatory bowel disease and risk of breast cancer: a meta-analysis of cohort studies. Eur J Cancer Prev. 2022;31:54\u201363.","journal-title":"Eur J Cancer Prev"},{"key":"7338_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/bjs5.71","volume":"2","author":"S Fujii","year":"2018","unstructured":"Fujii S, Ishibe A, Ota M, Watanabe K, Watanabe J, Kunisaki C, et al. Randomized clinical trial of high versus low inferior mesenteric artery ligation during anterior resection for rectal cancer. BJS Open. 2018;2:195\u2013202.","journal-title":"BJS Open"},{"key":"7338_CR19","first-page":"225","volume":"12","author":"JD Rudzki","year":"2019","unstructured":"Rudzki JD. Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs\u2014a controversial issue. memo - Magazine Eur Med Oncol. 2019;12:225\u20139.","journal-title":"memo - Magazine Eur Med Oncol"},{"key":"7338_CR20","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1093\/rheumatology\/keaa828","volume":"60","author":"K Hellgren","year":"2021","unstructured":"Hellgren K, Ballegaard C, Delcoigne B, Cordtz R, Nordstrom D, Aaltonen K, et al. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a nordic cohort study. Rheumatology (Oxford). 2021;60:3656\u201368.","journal-title":"Rheumatology (Oxford)"},{"key":"7338_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13075-022-02868-w","volume":"24","author":"B Choi","year":"2022","unstructured":"Choi B, Park HJ, Song YK, Oh YJ, Kim IW, Oh JM. The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study. Arthritis Res Ther. 2022;24:191.","journal-title":"Arthritis Res Ther"},{"key":"7338_CR22","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.7314\/APJCP.2014.15.8.3403","volume":"15","author":"Y Liu","year":"2014","unstructured":"Liu Y, Fan W, Chen H, Yu MX. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-alpha antagonist therapy: a meta-analysis of randomized control trials. Asian Pac J Cancer Prev. 2014;15:3403\u201310.","journal-title":"Asian Pac J Cancer Prev"},{"key":"7338_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"7338_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of Post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37:415\u201322.","journal-title":"Clin Drug Investig"},{"key":"7338_CR25","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","volume":"13","author":"X Tian","year":"2022","unstructured":"Tian X, Chen L, Gai D, He S, Jiang X, Zhang N. Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front Pharmacol. 2022;13:851246.","journal-title":"Front Pharmacol"},{"key":"7338_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/andr.13533","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhao B, Yang H, Wan Z. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil. Andrology. 2024;12:785\u201392.","journal-title":"Andrology"},{"key":"7338_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82:157\u201366.","journal-title":"Clin Pharmacol Ther"},{"key":"7338_CR28","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","volume":"14","author":"Y Wu","year":"2023","unstructured":"Wu Y, Wei M, Zhang J. A real-world pharmacovigilance analysis of FDA adverse event reporting system database for Upadacitinib. Front Pharmacol. 2023;14:1200254.","journal-title":"Front Pharmacol"},{"key":"7338_CR29","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang S, Wu Z, Xu L, Wen Q, Zhang X. Adverse reaction signals mining and hemorrhagic signals comparison of Ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS. Front Pharmacol. 2022;13:970066.","journal-title":"Front Pharmacol"},{"key":"7338_CR30","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902.","journal-title":"Front Pharmacol"},{"key":"7338_CR31","doi-asserted-by":"publisher","first-page":"1416985","DOI":"10.3389\/fphar.2024.1416985","volume":"15","author":"L He","year":"2024","unstructured":"He L, Li Q, Yang Y, Li J, Luo W, Huang Y, et al. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. Front Pharmacol. 2024;15:1416985.","journal-title":"Front Pharmacol"},{"key":"7338_CR32","doi-asserted-by":"publisher","first-page":"117791","DOI":"10.1016\/j.ecoenv.2025.117791","volume":"291","author":"N Song","year":"2025","unstructured":"Song N, Xi X, Yang K, Pei C, Zhao L. Effects of endocrine disrupting chemicals, blood metabolome, and epigenetics on breast cancer risk: A multi-dimensional Mendelian randomization study. Ecotoxicol Environ Saf. 2025;291:117791.","journal-title":"Ecotoxicol Environ Saf"},{"key":"7338_CR33","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ng.3406","volume":"47","author":"B Bulik-Sullivan","year":"2015","unstructured":"Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47:1236\u201341.","journal-title":"Nat Genet"},{"key":"7338_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ajhg.2017.09.022","volume":"101","author":"H Shi","year":"2017","unstructured":"Shi H, Mancuso N, Spendlove S, Pasaniuc B. Local genetic correlation gives insights into the shared genetic architecture of complex traits. Am J Hum Genet. 2017;101:737\u201351.","journal-title":"Am J Hum Genet"},{"key":"7338_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41588-017-0009-4","volume":"50","author":"P Turley","year":"2018","unstructured":"Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, et al. Multi-trait analysis of genome-wide association summary statistics using MTAG. Nat Genet. 2018;50:229\u201337.","journal-title":"Nat Genet"},{"key":"7338_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/978-1-4939-7274-6_22","volume":"1666","author":"X Li","year":"2017","unstructured":"Li X, Zhu X. Cross-Phenotype association analysis using summary statistics from GWAS. Methods Mol Biol. 2017;1666:455\u201367.","journal-title":"Methods Mol Biol"},{"key":"7338_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/ng.3506","volume":"48","author":"A Gusev","year":"2016","unstructured":"Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48:245\u201352.","journal-title":"Nat Genet"},{"key":"7338_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41588-019-0345-7","volume":"51","author":"Y Hu","year":"2019","unstructured":"Hu Y, Li M, Lu Q, Weng H, Wang J, Zekavat SM, et al. A statistical framework for cross-tissue transcriptome-wide association analysis. Nat Genet. 2019;51:568\u201376.","journal-title":"Nat Genet"},{"key":"7338_CR39","doi-asserted-by":"crossref","unstructured":"Nosratzehi S, Hashemi SM, Payandeh A, Bolouri A, Okati F. The relationship between breast cancer and thyroid autoimmune disorders in southeast Iran: a case-control study. Endocr Regul. 2024;58.","DOI":"10.2478\/enr-2024-0030"},{"key":"7338_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00403-019-01985-y","volume":"312","author":"TL Hung","year":"2020","unstructured":"Hung TL, Chen YL, Lin KT, Chiang CP, Chung CH, Hung CT, et al. Risk of radiotherapy-associated autoimmune bullous disease among Taiwanese patients with breast cancer: a case-control study. Arch Dermatol Res. 2020;312:69\u201375.","journal-title":"Arch Dermatol Res"},{"key":"7338_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial Research G","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial Research G. Etanercept plus standard therapy for wegener\u2019s granulomatosis. N Engl J Med. 2005;352:351\u201361.","journal-title":"N Engl J Med"},{"key":"7338_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2165\/0002018-200831120-00009","volume":"31","author":"HS de Vries","year":"2008","unstructured":"de Vries HS, van Oijen MG, de Jong DJ. Serious events with Infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf. 2008;31:1135\u201344.","journal-title":"Drug Saf"},{"key":"7338_CR43","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275\u201385.","journal-title":"JAMA"},{"key":"7338_CR44","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886\u201395.","journal-title":"Arthritis Rheum"},{"key":"7338_CR45","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/1878-0261.12905","volume":"15","author":"A Maia","year":"2021","unstructured":"Maia A, Gu Z, Koch A, Berdiel-Acer M, Will R, Schlesner M, et al. IFNbeta1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment. Mol Oncol. 2021;15:1308\u201329.","journal-title":"Mol Oncol"},{"key":"7338_CR46","doi-asserted-by":"publisher","first-page":"102747","DOI":"10.1016\/j.msard.2021.102747","volume":"49","author":"M Gomez-Moreno","year":"2021","unstructured":"Gomez-Moreno M, Sanchez-Seco VG, Moreno-Garcia S, Camara PS, Sabin-Munoz J, Ayuso-Peralta L, et al. Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. Mult Scler Relat Disord. 2021;49:102747.","journal-title":"Mult Scler Relat Disord"},{"key":"7338_CR47","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/jnnp-2013-307238","volume":"85","author":"E Kingwell","year":"2014","unstructured":"Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. Assessment of cancer risk with beta-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:1096\u2013102.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7338_CR48","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1074\/jbc.M115.679704","volume":"291","author":"I Kastrati","year":"2016","unstructured":"Kastrati I, Siklos MI, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, et al. Dimethyl fumarate inhibits the nuclear factor kappab pathway in breast cancer cells by covalent modification of p65 protein. J Biol Chem. 2016;291:3639\u201347.","journal-title":"J Biol Chem"},{"key":"7338_CR49","first-page":"177","volume":"18","author":"D Coradini","year":"1998","unstructured":"Coradini D, Pellizzaro C, Biffi A, Lombardi L, Pirronello E, Riva L, et al. Effect of liposome-encapsulated alpha- or beta-interferon on breast cancer cell lines. Anticancer Res. 1998;18:177\u201382.","journal-title":"Anticancer Res"},{"key":"7338_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123\u201334.","journal-title":"N Engl J Med"},{"key":"7338_CR51","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"7338_CR52","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1158\/1078-0432.CCR-04-0730","volume":"10","author":"S Madhusudan","year":"2004","unstructured":"Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res. 2004;10:6528\u201334.","journal-title":"Clin Cancer Res"},{"key":"7338_CR53","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1038\/s41467-021-25189-z","volume":"12","author":"R Taftaf","year":"2021","unstructured":"Taftaf R, Liu X, Singh S, Jia Y, Dashzeveg NK, Hoffmann AD, et al. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat Commun. 2021;12:4867.","journal-title":"Nat Commun"},{"key":"7338_CR54","doi-asserted-by":"publisher","first-page":"20240969","DOI":"10.1515\/med-2024-0969","volume":"19","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Fan J, Wang X, Wu Z, Ma W, Ma B. Role of ICAM-1 in triple-negative breast cancer. Open Med (Wars). 2024;19:20240969.","journal-title":"Open Med (Wars)"},{"key":"7338_CR55","doi-asserted-by":"publisher","first-page":"e76403","DOI":"10.1371\/journal.pone.0076403","volume":"8","author":"JJ Krais","year":"2013","unstructured":"Krais JJ, De Crescenzo O, Harrison RG. Purine nucleoside phosphorylase targeted by Annexin v to breast cancer vasculature for enzyme prodrug therapy. PLoS ONE. 2013;8:e76403.","journal-title":"PLoS ONE"},{"key":"7338_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11095-018-2448-8","volume":"35","author":"F Weber","year":"2018","unstructured":"Weber F, Breustedt D, Schlicht S, Meyer CA, Niewoehner J, Ebeling M, et al. First infusion reactions are mediated by FcgammaRIIIb and neutrophils. Pharm Res. 2018;35:169.","journal-title":"Pharm Res"},{"key":"7338_CR57","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/CAD.0000000000001685","volume":"36","author":"H Xiang","year":"2025","unstructured":"Xiang H, Tu B, Feng X, Chen L, Huang Y. Dual Inhibition of TYK2 and PD-L1 boosts immune response in triple negative breast cancer. Anticancer Drugs. 2025;36:280\u20139.","journal-title":"Anticancer Drugs"},{"key":"7338_CR58","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2174\/1568009622666220921103201","volume":"23","author":"N Syed","year":"2023","unstructured":"Syed N, Ilyas A, Syed B, Ahmed A, Zarina S, Hashim Z. Novel synergistic combination of pamidronate and Temozolomide for breast cancer therapeutics. Curr Cancer Drug Targets. 2023;23:222\u201334.","journal-title":"Curr Cancer Drug Targets"},{"key":"7338_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12935-018-0707-8","volume":"18","author":"S Gutierrez","year":"2018","unstructured":"Gutierrez S, Boada MD. Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231(LUC+)). Cancer Cell Int. 2018;18:216.","journal-title":"Cancer Cell Int"},{"key":"7338_CR60","doi-asserted-by":"publisher","first-page":"106652","DOI":"10.1016\/j.jsbmb.2024.106652","volume":"246","author":"Y Lin","year":"2025","unstructured":"Lin Y, Wang S, Zhang Y, She J, Zhang Y, Zhao R, et al. Drug repurposing opportunities for breast cancer and seven common subtypes. J Steroid Biochem Mol Biol. 2025;246:106652.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"7338_CR61","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/hmg\/ddae024","volume":"33","author":"DA Michalek","year":"2024","unstructured":"Michalek DA, Tern C, Zhou W, Robertson CC, Farber E, Campolieto P, et al. A multi-ancestry genome-wide association study in type 1 diabetes. Hum Mol Genet. 2024;33:958\u201368.","journal-title":"Hum Mol Genet"},{"key":"7338_CR62","doi-asserted-by":"publisher","first-page":"e1002293","DOI":"10.1371\/journal.pgen.1002293","volume":"7","author":"JP Bradfield","year":"2011","unstructured":"Bradfield JP, Qu HQ, Wang K, Zhang H, Sleiman PM, Kim CE, et al. A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet. 2011;7:e1002293.","journal-title":"PLoS Genet"},{"key":"7338_CR63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.14715\/cmb\/2024.70.11.3","volume":"70","author":"Z Torki","year":"2024","unstructured":"Torki Z, Ghavi D, Foruzandeh Z, Zeinali Sehrig F, Hashemi S, Alivand MR, et al. Network-based meta-analysis and confirmation of genes ATP1A2, FXYD1, and ADCY3 associated with cAMP signaling in breast tumors compared to corresponding normal marginal tissues. Cell Mol Biol (Noisy-le-grand). 2024;70:16\u201330.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"7338_CR64","doi-asserted-by":"crossref","unstructured":"Al-Harazi O, El Allali A, Kaya N, Colak D. Identification of diagnostic and prognostic subnetwork biomarkers for women with breast cancer using integrative genomic and network-based analysis. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms252312779"},{"key":"7338_CR65","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","volume":"56","author":"R Neha","year":"2021","unstructured":"Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength. Hosp Pharm. 2021;56:152\u20138.","journal-title":"Hosp Pharm"},{"key":"7338_CR66","doi-asserted-by":"publisher","first-page":"R195","DOI":"10.1093\/hmg\/ddy163","volume":"27","author":"G Hemani","year":"2018","unstructured":"Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of Pleiotropy in Mendelian randomization studies. Hum Mol Genet. 2018;27:R195\u2013208.","journal-title":"Hum Mol Genet"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07338-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07338-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:03:45Z","timestamp":1763741025000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07338-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7338"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07338-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1332"}}